Citation Impact
Citing Papers
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
2012 StandoutNobel
Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy
2011 StandoutNobel
Multiple Antitumor Mechanisms Downstream of Prophylactic Regulatory T-Cell Depletion
2010 StandoutNobel
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
1998
Cancer immunoediting: from immunosurveillance to tumor escape
2002 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
The Thymic Repertoire of Neuroendocrine-Related Self Antigens: Biological Role in T-Cell Selection and Pharmacological Implications
1999
Antigenic peptide nanofibers elicit adjuvant-free CD8+ T cell responses
2013
Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers
2000
Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts
1996
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Eradication of Established Tumors by CD8+ T Cell Adoptive Immunotherapy
2000
Human tumor antigens recognized by T-cells
1997
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
2003 Standout
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
1998 StandoutNature
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
2015 Standout
Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
1999 StandoutNobel
Papillomaviruses and cancer: from basic studies to clinical application
2002 StandoutNobel
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function
2001 StandoutNobel
Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses
2002
Strategies for immunotherapy of cancer
2000
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Dendritic Cells
1999
Memory of Extracellular Adenosine A2A Purinergic Receptor-mediated Signaling in Murine T Cells
1997 StandoutNobel
Mature dendritic cells boost functionally superior CD8+ T-cell in humans without foreign helper epitopes
2000 StandoutNobel
Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes
1998 Standout
Cancer vaccines
1998
Immunity to Melanoma Antigens: From Self‐Tolerance to Immunotherapy
2006
Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
2010 StandoutNobel
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
2001 StandoutNature
Breaking down the barriers to cancer immunotherapy
2005 StandoutNobel
Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways
2003 StandoutNobel
Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12
1999
Enhancement of Tumor Outgrowth Through CTL Tolerization After Peptide Vaccination Is Avoided by Peptide Presentation on Dendritic Cells
1998
Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance
1999
Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
1999 StandoutNobel
Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein
1999
The CD8+ Dendritic Cell Subset Selectively Endocytoses Dying Cells in Culture and In Vivo
2002 StandoutNobel
Peptide Vaccine Induces Enhanced Tumor Growth Associated with Apoptosis Induction in CD8+ T Cells
2010
Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70
2000 StandoutNobel
Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials
2015 Standout
Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responsesin vitroandin vivo
1998
DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8 + T cells in a spectrum of human MHC I haplotypes
2007 StandoutNobel
Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo
2003
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells
2004 StandoutNobel
Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma
1999 StandoutNobel
Phase I Trial of a CD8+T-Cell Peptide Epitope-Based Vaccine for Infectious Mononucleosis
2007
Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Linkage ofMycobacterium tuberculosisHeat Shock Protein 70 Gene to an Antigen Gene
2001 StandoutNobel
High Avidity CTLs for Two Self-Antigens Demonstrate Superior In Vitro and In Vivo Antitumor Efficacy
1999
Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model
1998
Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC.
1998
Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine
2001 StandoutNobel
Cutting Edge: Cross-Priming of CTL Responses In Vivo Does Not Require Antigenic Peptides in the Endoplasmic Reticulum of Immunizing Cells
1998
TNF-Mediated Toxicity After Massive Induction of Specific CD8+ T Cells Following Immunization of Mice with a Tumor-Specific Peptide
2002
Cross-Presentation of Glycoprotein 96–Associated Antigens on Major Histocompatibility Complex Class I Molecules Requires Receptor-Mediated Endocytosis
1999
Status of Activation of Circulating Vaccine-Elicited CD8+ T Cells
2000
Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer
2005 StandoutNobel
Protective antitumor immunity induced by immunization with completely allogeneic tumor cells.
1996
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
2001 StandoutNobel
Decreased tumor surveillance in perforin-deficient mice.
1996
Cross-priming of CTL responses in vivo does not require antigenic peptides in the endoplasmic reticulum of immunizing cells.
1998
Cell-free tumor antigen peptide-based cancer vaccines
1997
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells
2005 StandoutNobel
Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication
2004
Conversion of Alloantigen-Specific CD8+ T Cell Anergy to CD8+ T Cell Priming through In Vivo Ligation of Glucocorticoid-Induced TNF Receptor
2006 StandoutNobel
CD4+ T Cells Are Able to Promote Tumor Growth through Inhibition of Tumor-Specific CD8+ T-Cell Responses in Tumor-Bearing Hosts
2005
CRYOSURGICAL ABLATION OF THE NORMAL VENTRAL PROSTATE PLUS ADJUVANT DOES NOT PROTECT COPENHAGEN RATS FROM DUNNING PROSTATIC ADENOCARCINOMA CHALLENGE
1997
Dendritic Cells Charged with Apoptotic Tumor Cells Induce Long-Lived Protective CD4+ and CD8+ T Cell Immunity against B16 Melanoma
2003 StandoutNobel
Absence of Programmed Death Receptor 1 Alters Thymic Development and Enhances Generation of CD4/CD8 Double-Negative TCR-Transgenic T Cells
2003 StandoutNobel
Immunobiology of Dendritic Cells
2000 Standout
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy
2001 StandoutNobel
Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors
1998
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
The Oxytocin Receptor System: Structure, Function, and Regulation
2001 Standout
Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses
2008 StandoutNobel
Receptor-Mediated Uptake of Antigen/Heat Shock Protein Complexes Results in Major Histocompatibility Complex Class I Antigen Presentation via Two Distinct Processing Pathways
1999 StandoutNobel
Therapeutic cancer vaccines
2015
Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
2003
Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus
1999 StandoutNobel
Adoptive T Cell Immunotherapy of Human Uveal Melanoma Targeting gp100
2000
Cutting Edge: A Crucial Role for B7-CD28 in Transmitting T Help from APC to CTL
2002 StandoutNobel
Immunization with a Lymphocytic Choriomeningitis Virus Peptide Mixed with Heat Shock Protein 70 Results in Protective Antiviral Immunity and Specific Cytotoxic T Lymphocytes
1998
Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
2005 StandoutNobel
Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor Regression
1999
Expression of the Serpin Serine Protease Inhibitor 6 Protects Dendritic Cells from Cytotoxic T Lymphocyte–Induced Apoptosis
2001
Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus
1999 StandoutNobel
Works of R. Blom being referenced
In vivo detection of fluorescent tumor-specific cytotoxic T cell clones
1993
Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.
1996
Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
1996
An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene.
1995